Anti-VEGF therapy in pituitary carcinoma

Pituitary

Volumn 15, Issue 3, 2012, Pages 445-449

  Ortiz, Leon D ^a   Syro, Luis V ^b   Scheithauer, Bernd W ^c   Ersen, Ayca ^d   Uribe, Humberto ^e   Fadul, Camilo E ^f   Rotondo, Fabio ^g   Horvath, Eva ^g   Kovacs, Kalman ^g  

^a Section of Neuro oncology   (Colombia)

^b HOSPITAL PABLO TOBÓN URIBE   (Colombia)

^c MAYO CLINIC   (United States)

^d DOKUZ EYLUL UNIVERSITY   (Turkey)

^e Clinica SOMA   (Colombia)

^f DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^g ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Angiogenesis inhibitors; Bevacizumab; Pituitary carcinoma; Temozolomide; Vascular endothelial growth factor A

Indexed keywords

BEVACIZUMAB; TEMOZOLOMIDE; VASCULOTROPIN ANTIBODY;

ACTH SECRETING ADENOMA; ADULT; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CONTROL; CARCINOMA; CASE REPORT; CELL DAMAGE; CONTINUOUS INFUSION; DISEASE COURSE; DRUG RESPONSE; FIBROSIS; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS CARCINOMA; HYPOPHYSIS DISEASE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SPINE METASTASIS; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR BIOPSY; VASCULAR DISEASE;

ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DACARBAZINE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PITUITARY NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867398371     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-011-0346-8     Document Type: Article

References (27)

1. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8(8):579-591. doi:10.1038/nrc2403
2. Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O, Yee H, Voura EB, Newcomb EW (2006) Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 86(12):1221-1232. doi:10.1038/labinvest.3700482
3. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo. Nature 362(6423):841-844. doi:10.1038/362841a0
4. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19): 2039-2049. doi:10.1056/NEJMra0706596
5. Wilson WR, Hay MP (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11(6):393-410. doi:10.1038/nrc3064
6. Gaur P, Bose D, Samuel S, Ellis LM (2009) Targeting tumor angiogenesis. Semin Oncol 36(2 suppl 1):S12-S19. doi:10.1053/j.seminoncol.2009.02.002
7. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular agerelated macular degeneration. N Engl J Med 364(20):1897-1908. doi:10.1056/NEJMoa1102673
8. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182-1186. doi:10.1056/NEJM1971111 82852108
9. Moshkin O, Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Uribe H, Gonzalez R, Cusimano M, Horvath E, Rotondo F, Kovacs K (2011) Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of temozolomide therapy. Hormones (Athens) 10(2):162-167
10. Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353(2):172-187. doi:10.1056/NEJMra044389
11. Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333(2):328-335. doi:10.1016/j.bbrc.2005.05.132
12. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57(20):4593-4599
13. Chamberlain MC, Johnston S (2009) Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol 91(3):359-367. doi:10.1007/s11060-008- 9722-2
14. Jouanneau E (2008) Angiogenesis and gliomas: current issues and development of surrogate markers. Neurosurgery 62(1):31-50. doi:10.1227/01.NEU. 0000311060.65002.4E00006123- 200801000-00003 discussion 50-32
15. Norden AD, Drappatz J, Wen PY (2008) Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol 20(6):652-661. doi:10.1097/CCO. 0b013e32831186ba00001622-200811000-00009
16. Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A, Kesari S, Wen PY (2009) An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 92(2):149-155. doi:10.1007/s11060-008-9745-8
17. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM (2010) Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120(3):694-705. doi:10.1172/JCI4028340283
18. Torcuator R, Zuniga R, Mohan YS, Rock J, Doyle T, Anderson J, Gutierrez J, Ryu S, Jain R, Rosenblum M, Mikkelsen T (2009) Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 94(1):63-68. doi:10.1007/s11060-009-9801-z
19. Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, Uribe H, Cusimano M, Kovacs K, Horvath E (2011) Treatment of pituitary neoplasms with temozolomide: a review. Cancer 117(3):454-462. doi:10.1002/cncr.25413
20. McCormack AI, Wass JA, Grossman AB (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest. doi:10.1111/j.1365-2362.2011.02520.x
21. Tebbutt NC, Murphy F, Zannino D, Wilson K, Cummins MM, Abdi E, Strickland AH, Lowenthal RM, Marx G, Karapetis C, Shannon J, Goldstein D, Nayagam SS, Blum R, Chantrill L, Simes RJ, Price TJ (2011) Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Ann Oncol 22(8):1834-1838. doi:10.1093/annonc/mdq702
22. Norden AD, Drappatz J, Ciampa AS, Doherty L, LaFrankie DC, Kesari S, Wen PY (2009) Colon perforation during antiangiogenic therapy for malignant glioma. Neuro Oncol 11(1):92-95. doi:10.1215/15228517-2008-071
23. Helfrich I, Scheffrahn I, Bartling S, Weis J, von Felbert V, Middleton M, Kato M, Ergun S, Schadendorf D (2010) Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 207(3):491-503. doi:10.1084/jem.20091846
24. Azam F, Mehta S, Harris AL (2010) Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer 46(8):1323-1332. doi:10.1016/j.ejca.2010. 02.020
25. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3):220-231. doi:10.1016/j.ccr.2009.01.027
26. Cheshier SH, Kalani MY, Lim M, Ailles L, Huhn SL, Weissman IL (2009) A neurosurgeon's guide to stem cells, cancer stem cells, and brain tumor stem cells. Neurosurgery 65(2):237-249. doi:10.1227/01.NEU.0000349921.14519. 2A00006123-200908000- 00003; discussion 249-250; quiz N236
27. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733-4740. doi:10.1200/JCO.2008.19.8721